JavaScript scheint in Ihrem Browser deaktiviert zu sein. Sie müssen JavaScript in Ihrem Browser aktivieren, um alle Funktionen in diesem Shop nutzen zu können.
Hepatocellular carcinoma Origin: Established from the tumor tissue of a 15-year-old Argentine boy Species:Homo sapiens Tissue:Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Established from the tumor tissue of a 15-year-old Argentine boy Species:Homo sapiens Tissue:Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Homo sapiens Tissue:Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Mutations in HepG2 Cells
Hep3B cells
HepG2 cells
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.
C0015002.pdf
Sicherheitsdatenblatt anfordern
Lieferung vsl. bis 31.07.2025
Vergleichen
Auf den Wunschzettel
Angebot anfordern
Lieferzeit anfragen
Technische Frage stellen
Bulk-Anfrage stellen
sales@hoelzel.de
« Zurück
Pünktliche Lieferung zu Ihrem Wunschtermin und bei jeder 5. Bestellung 15% sparen.
Passwort vergessen?
Noch nicht registriert? Konto hier erstellen!